- Case report
- Open Access
- Open Peer Review
A 4-month-old baby presenting with dermal necrotizing granulomatous giant cell reaction at the injection site of 13-valent pneumococcal conjugate vaccine: a case report
© Alsuwaidi et al.; licensee BioMed Central Ltd. 2014
- Received: 23 January 2014
- Accepted: 12 July 2014
- Published: 24 August 2014
Adjuvants (for example, aluminum salts) are frequently incorporated in licensed vaccines to enhance the host immune response. Such vaccines include the pneumococcal conjugate, combinations of diphtheria–tetanus/acellular pertussis, tetanus– diphtheria/acellular pertussis, hepatitis B, some Haemophilus influenzae type b, hepatitis A, and human papillomavirus. These preparations have been associated with complicated local adverse events, especially if administered subcutaneously or intradermally in comparison to deep intramuscular injection. We describe a severe inflammatory reaction at the site of an injection of 13-valent pneumococcal conjugate vaccine.
A 4-month-old Arab baby boy developed dermal necrotizing granulomatous giant cell reaction at the injection site (right anterior thigh) of the second dose of 13-valent pneumococcal conjugate vaccine. Ziehl–Neelsen and periodic-acid Schiff were negative. This reaction probably resulted from improper intramuscular administration because the first (at 2 months of age) and third (at 10 months of age) doses were uneventful.
Dermal necrotizing granulomatous reactions are a serious complication of the 13-valent pneumococcal conjugate vaccine. Health care providers need to administer this preparation deeply into a muscle mass. Completing the vaccine series is an acceptable option. Physicians are encouraged to report their experience with completing vaccine series following adverse events.
- Adverse events
- Necrotizing granulomatous giant cell reaction
- Pneumococcal conjugate vaccine
Introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) has resulted in a substantial drop in the rate of invasive pneumococcal disease. However, non-vaccine serotypes have emerged. The 13-valent pneumococcal conjugate vaccine (PCV13) was subsequently developed and is currently used in many countries.
The safety profile of PCV13 is similar to that of PCV7. Local reactions are common including tenderness (47%), swelling (29%), and redness (36%). These adverse events are usually mild and occur after any dose of the infant series.
We describe a severe dermal inflammatory reaction at the site of the injection of the second PCV13 dose. The report aims at improving vaccination safety.
At 10 weeks, the area appeared better; the swelling and other clinical signs were regressing. He received the third PCV13 dose at 10 months of age and the injection was uneventful.
The precise mechanism of this prolonged and deleterious inflammatory reaction to PCV13 remains obscure. Adjuvants, such as aluminum salts, are frequently incorporated in licensed vaccines (including PCV13) to enhance the host immune response. Local reactions (for example, granuloma formation) induced by these adjuvants are relatively common.
Bordet et al. have reported cases of subcutaneous nodules with a necrotizing granulomatous reaction at the site of a previous injection of the aluminum hydroxide-containing vaccine, Tetracoq® (tetanus, diphtheria, Bordetella pertussis, poliovirus). Several cases of persistent itchy subcutaneous nodules (lasting for years) and hypersensitivity to aluminum after diphtheria–tetanus/acellular pertussis/polio+Hib vaccination have been also described. Consistently, one study in pigs demonstrated that aluminum hydroxide could invoke a granulomatous reaction.
The American Academy of Pediatrics recommends that administration of vaccines containing adjuvants (for example, aluminum present in vaccines recommended for intramuscular injection including PCV13) should be deep into a muscle mass. Subcutaneous or intradermal injections of these preparations are associated with an increased incidence of local irritation, inflammation, granuloma formation, and tissue necrosis.
This baby had no adverse events following the first and third PCV13 doses. Thus, it is unlikely that the observed response to the second PCV13 dose was an allergic reaction. It is probable that an improper technique of administration was responsible for this reaction. Proving this possibility retrospectively, however, is difficult.
The specific stains and cultures did not support mycobacterial or fungal infection. The positive wound bacterial culture was most probably a secondary hospital-acquired infection and managed with a proper antibiotic. The initial antibiotic course, however, was empiric for a suspected cellulitis.
Dermal necrotizing granulomatous giant cell reaction is a serious complication of the 13-valent pneumococcal conjugate vaccine. These lesions require only conservative treatment. Babies may react to any dose of the vaccine series. Physicians are encouraged to report their experience with completing vaccine series following adverse events. Appropriate administration technique of adjuvant-containing vaccines is crucial.
Written informed consent was obtained from the patient’s parent for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, Smith PJ, Beall BW, Whitney CG, Moore MR, Active Bacterial Core Surveillance/Emerging Infections Program Network: Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010, 201 (1): 32-41. 10.1086/648593.View ArticlePubMedGoogle Scholar
- Thompson A, Gurtman A, Patterson S, Juergens C, Laudat F, Emini EA, Gruber WC, Scott DA: Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries. Vaccine. 2013, 31 (45): 5289-5295. 10.1016/j.vaccine.2013.08.025.View ArticlePubMedGoogle Scholar
- Leroux-Roels G: Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine. 2010, 28 (Suppl 3): C25-C36.View ArticlePubMedGoogle Scholar
- Batista-Duharte A, Lindblad EB, Oviedo-Orta E: Progress in understanding adjuvant immunotoxicity mechanisms. Toxicol Lett. 2011, 203 (2): 97-105. 10.1016/j.toxlet.2011.03.001.View ArticlePubMedGoogle Scholar
- Bordet AL, Michenet P, Cohen C, Arbion F, Ekindi N, Bonneau C, Kerdraon R, Coville M: Post-vaccination granuloma due to aluminium hydroxide. Ann Pathol. 2001, 21 (2): 149-152.PubMedGoogle Scholar
- Bergfors E, Björkelund C, Trollfors B: Nineteen cases of persistent pruritic nodules and contact allergy to aluminium after injection of commonly used aluminium-adsorbed vaccines. Eur J Pediatr. 2005, 164 (11): 691-697. 10.1007/s00431-005-1704-1.View ArticlePubMedGoogle Scholar
- Valtulini S, Macchi C, Ballanti P, Cherel Y, Laval A, Theaker JM, Bak M, Ferretti E, Morvan H: Aluminium hydroxide-induced granulomas in pigs. Vaccine. 2005, 23 (30): 3999-4004. 10.1016/j.vaccine.2004.06.058.View ArticlePubMedGoogle Scholar
- American Academy of Pediatrics: Red Book: 2012 Report of the Committee on Infectious Diseases. Edited by: Pickering LK. 2012, Elk Grove Village, IL: American Academy of Pediatrics, 29Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.